Here are 1-3 brief analogies to describe Tarsus Pharmaceuticals (TARS):

• It's like a clinical-stage Allergan, but intensely focused on developing new prescription drugs for specific eye and skin conditions like blepharitis and rosacea.

• Think of it as a biotech startup aiming to be the 'Vertex Pharmaceuticals' for underserved eye and skin diseases, leveraging a promising molecule across different conditions.

Major Products:

• TP-03: A therapeutic candidate in Phase III for blepharitis caused by Demodex mites and meibomian gland disease.
• TP-04: A therapeutic candidate in development for the treatment of rosacea.
• TP-05: A therapeutic candidate in development for Lyme prophylaxis and community malaria reduction.
• Lotilaner: A compound being developed to address diseases across various therapeutic categories in human medicine.

Tarsus Pharmaceuticals, Inc. (TARS) is a clinical-stage biopharmaceutical company. As such, it is focused on the development of novel therapeutic candidates and does not currently have major commercial customers for approved products generating revenue from drug sales.

However, upon successful development and commercialization of its therapeutic candidates, Tarsus Pharmaceuticals would primarily sell its products to other companies within the pharmaceutical supply chain, rather than directly to individuals. The major categories of these customers would include:

1. Pharmaceutical Wholesalers and Distributors: These companies purchase drugs directly from manufacturers and distribute them to pharmacies, hospitals, and other healthcare providers. Examples of such public companies include McKesson Corporation (MCK), AmerisourceBergen Corporation (ABC), and Cardinal Health, Inc. (CAH).
2. Retail Pharmacy Chains and Hospital Systems: Large pharmacy chains and hospital networks purchase pharmaceutical products for dispensing to patients. Examples of public pharmacy chains include CVS Health Corporation (CVS) and Walgreens Boots Alliance, Inc. (WBA).
3. Pharmacy Benefit Managers (PBMs) and Health Insurers: While not direct purchasers in the same way as wholesalers, PBMs and health insurers play a critical role in controlling market access and reimbursement for pharmaceutical products. Their decisions on formulary inclusion and pricing significantly impact a drug's commercial success, effectively making them key "customers" in the value chain. Examples of public companies with significant PBM operations include CVS Health Corporation (CVS) through Caremark, UnitedHealth Group (UNH) through OptumRx, and The Cigna Group (CI) through Express Scripts.

Bobak Azamian, M.D., Ph.D. Chief Executive Officer

Dr. Bobak Azamian is a co-founder and the CEO of Tarsus Pharmaceuticals. He co-founded and led other novel therapeutics companies, including Vibrato Medical and Metavention, where he also served as CEO and Chief Medical Officer. Dr. Azamian began his biotechnology career as an investor and board observer with Versant Ventures and Third Rock Ventures. He has provided leadership and strategic guidance through discovery, development, and commercialization, and has raised over $150M.

Jeff Farrow Chief Financial Officer and Chief Strategy Officer

Jeff Farrow assumed the role of Chief Financial Officer and Chief Strategy Officer at Tarsus Pharmaceuticals in April 2023. He brings over two decades of experience in biotech, having previously served as CFO of Global Blood Therapeutics, Inc., where he was instrumental in securing regulatory approval and commercializing the medication Oxbryta. Mr. Farrow also held CFO roles at ZS Pharma and Hyperion Therapeutics, Inc., providing strategic and financial leadership for product development.

Aziz Mottiwala Chief Commercial Officer

Aziz Mottiwala has more than 20 years of leadership experience in the biopharmaceutical industry, encompassing all facets of commercialization across various therapeutic areas, with over 10 years specifically in the Eye Care sector. Prior to joining Tarsus, Mr. Mottiwala was the Chief Commercial Officer at Opiant Pharmaceuticals.

Sesha Neervannan, Ph.D. Chief Operating Officer

Dr. Sesha Neervannan serves as the Chief Operating Officer at Tarsus Pharmaceuticals.

Elizabeth Yeu, M.D. Chief Medical Officer

Dr. Elizabeth Yeu is the Chief Medical Officer at Tarsus Pharmaceuticals. She is also a partner at Virginia Eye Consultants and holds a position as an Executive Committee member and the current Secretary for the American Society of Cataract and Refractive Surgery (ASCRS).

Key Business Risks for Tarsus Pharmaceuticals (TARS)

The key risks for Tarsus Pharmaceuticals (TARS) primarily revolve around its status as a clinical-stage biopharmaceutical company with a lead product candidate in late-stage development.

1. Clinical Trial Failure and Regulatory Approval Risk: Tarsus Pharmaceuticals' lead product candidate, TP-03, is currently in Phase III clinical trials for the treatment of blepharitis. A significant risk for the company is the potential failure of these pivotal clinical trials to meet their endpoints or demonstrate sufficient safety and efficacy. Even if trials are successful, there remains a substantial risk that the company may not obtain the necessary regulatory approvals (e.g., from the FDA) for TP-03 or any other pipeline candidates. A setback at this stage would represent a substantial loss of investment and could severely impact the company's future viability and ability to bring products to market.
2. Commercialization and Market Adoption Risk: Assuming successful clinical development and regulatory approval for TP-03 or other product candidates, Tarsus Pharmaceuticals faces the challenge of effective commercialization and achieving market acceptance. The company would need to successfully launch and market its products, competing with existing or future treatments for ophthalmic conditions, rosacea, Lyme prophylaxis, and malaria reduction. Factors such as pricing, reimbursement, physician prescribing habits, and patient adoption could significantly impact the commercial success and revenue generation of its products.
3. Intellectual Property and Competition Risk: The long-term success of Tarsus Pharmaceuticals depends heavily on its ability to obtain, maintain, and enforce intellectual property protection for its product candidates, particularly those based on lotilaner. The risk includes challenges to the validity or scope of its patents, potential infringement by competitors, or the emergence of new, more effective, or lower-cost therapies that could reduce the market share and profitability of Tarsus's products.

Tarsus Pharmaceuticals (symbol: TARS) is developing novel therapeutic candidates for several ophthalmic conditions and infectious diseases, targeting significant addressable markets.

TP-03 (XDEMVY) for Demodex Blepharitis and Meibomian Gland Disease

• Demodex Blepharitis: This condition affects as many as 25 million Americans. The global blepharitis market, which includes Demodex blepharitis (responsible for over two-thirds of all blepharitis cases), is projected to reach approximately USD 2.7 billion by 2030, growing from an estimated USD 1.9 billion in 2024. Specifically, the U.S. blepharitis market is estimated at USD 0.76 billion in 2024 and is projected to reach approximately USD 1.08 billion by 2030. Tarsus's XDEMVY (lotilaner ophthalmic solution) 0.25% is the first FDA-approved treatment for Demodex blepharitis in the United States.
• Meibomian Gland Disease (MGD): The global meibomian gland dysfunction market was valued at USD 4.42 billion in 2025 and is projected to grow to USD 6.12 billion by 2030. In the 7 major markets (U.S., EU4, U.K., and Japan), the meibomian gland dysfunction market reached USD 2.3 billion in 2024 and is expected to reach USD 4.9 billion by 2035. The U.S. meibomian gland dysfunction market was estimated at US$ 1,976.6 million in 2020 and is expected to surpass US$ 8,292.0 million by 2030. North America holds approximately 45% of the global market share for MGD treatments.

TP-04 for Rosacea

• The global rosacea treatment market was estimated at USD 2.08 billion in 2024 and is projected to increase to approximately USD 4.23 billion by 2034. Ocular rosacea, which TP-04 targets, affects an estimated 15-18 million Americans. North America held the largest revenue share of 38.7% in the rosacea treatment market in 2024.

TP-05 for Lyme Prophylaxis and Community Malaria Reduction

• Lyme Prophylaxis (Lyme Disease Prevention/Treatment): The global Lyme disease treatment market was valued at USD 737.5 million in 2021 and is projected to reach USD 1.6 billion by 2031. Another estimate places the global market at USD 1.45 billion in 2025, expected to reach USD 2.30 billion by 2032. The U.S. reports around half a million cases of Lyme disease each year. North America accounted for $465.1 million of the Lyme disease treatment market in 2021 and is expected to generate the highest revenue in the market by the end of 2031.
• Community Malaria Reduction (Malaria Prevention/Treatment): The global anti-malarial drugs market size was valued at USD 989.7 million in 2023 and is expected to grow to USD 1.67 billion by 2034. The malaria treatment market size is expected to grow from $1.61 billion in 2025 to $2.18 billion in 2030.

Tarsus Pharmaceuticals (symbol: TARS) is expected to experience significant future revenue growth over the next 2-3 years, primarily driven by three key areas:

1. Global Expansion and Market Penetration of XDEMVY® for Demodex Blepharitis: Tarsus Pharmaceuticals' lead product, XDEMVY (lotilaner ophthalmic solution, 0.25%), for the treatment of Demodex blepharitis, is a primary driver of anticipated revenue growth. Following a strong launch, with net product sales of $451.4 million in 2025, management projects U.S. peak sales potential to exceed $2 billion. For 2026, the company has provided guidance for net product sales ranging from $670 million to $700 million, indicating an annual growth of over 50% at the midpoint. This growth is fueled by strategic initiatives including expanding its sales force, achieving broader payer coverage (reaching over 90% of commercial and Medicare/Medicaid lives), and effective direct-to-consumer (DTC) engagement campaigns that have significantly increased patient awareness and prescriber adoption. Furthermore, the company is pursuing global regulatory approvals for XDEMVY (TP-03), with potential approval in China in 2026 and Europe in 2027, which will further expand its market reach.
2. Advancement and Potential Approval of TP-04 for Ocular Rosacea: Tarsus is developing TP-04, an investigational ophthalmic gel formulation of lotilaner, for the treatment of ocular rosacea. This condition affects an estimated 15-18 million Americans and currently has no FDA-approved therapies, presenting a significant unmet medical need and a category-creating opportunity for Tarsus. The company initiated a Phase 2 study for TP-04 in December 2025, with top-line results anticipated in the first half of 2027. Successful progression and potential approval of TP-04 would open a new therapeutic area and revenue stream. Patent exclusivity for TP-04 is expected to extend through 2038, offering a long-term competitive advantage.
3. Progression of TP-05 for Lyme Disease Prevention and Malaria Reduction: Tarsus is also advancing TP-05, an investigational oral systemic formulation of lotilaner, for the prevention of Lyme disease and community malaria reduction. TP-05 is positioned as the only non-vaccine, drug-based prophylactic in development designed to kill ticks to potentially prevent Lyme disease transmission. The company plans to initiate a Phase 2 study for TP-05 for Lyme prevention in the second quarter of 2026, with top-line results expected in the first half of 2027. Additionally, the TP-05 formulation is progressing into Phase 1 studies for malaria. The successful development and commercialization of TP-05 would diversify Tarsus's revenue streams beyond ophthalmology into infectious disease prevention.

Share Issuance

• Tarsus Pharmaceuticals completed a follow-on public offering in March 2025, raising $134.8 million to support its operations.
• The company has actively managed its capital through multiple public offerings, reflecting a strategy to raise significant funds for its operations.
• A shelf registration for $141.73 million was filed after the 2025 results, indicating potential future share issuances.

Capital Expenditures

• In the last 12 months, Tarsus Pharmaceuticals reported capital expenditures of -$9.86 million.
• Forecasted capital expenditures (CAPEX) for Tarsus Pharmaceuticals include values such as 0.456, 0.586, 0.506, and 3.292 (presumably in millions).
• The company anticipates expanding its development, regulatory, and operational capabilities, which would necessitate capital investment.